Annals of Vascular Surgery

, Volume 19, Issue 1, pp 130–138 | Cite as

Atherosclerosis as Inflammation

  • Philip S. Mullenix
  • Charles A. Andersen
  • Benjamin W. Starnes
Basic Science Review
  • 91 Downloads

Abstract

Atherosclerosis has traditionally been attributed to disordered cholesterol metabolism with associated accumulation of lipid substrate in the arterial wall. It is now believed that systemic and local inflammatory events mediate all phases of plaque development, progression, and degeneration. No longer regarded as a bland, mechanical process, plaque evolution is now best understood as a pitched battle between proinflammatory and anti-inflammatory cellular and molecular elements. Not unlike models of chronic wound healing or ischemia-reperfusion, the biologic state of a plaque at any given time is transient and mutable, reflecting a dynamic balance of numerous local and circulating inflammatory forces. Dreaded complications of the disease such as myocardial infarction and stroke result from acute shifts in this balance in favor of plaque instability and vulnerability over stable states of chronic inflammation. The purpose of this article is (1) to review the inflammatory pathogenesis of atherosclerosis on a molecular basis, (2) describe several of the emerging inflammatory biomarkers currently being investigated with particular interest in their possible roles as direct mediators of vascular disease, and (3) identify several important implications for diagnosis and therapy.

References

  1. 1.
    Ross, R 1999Atherosclerosis — an inflammatory diseaseN Engl J Med340115126CrossRefPubMedGoogle Scholar
  2. 2.
    Ross, R, Glomset, JA 1953Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosisScience18013321339CrossRefGoogle Scholar
  3. 3.
    Ross, R, Glomset, JA 1976The pathogenesis of antherosclerosisN Engl J Med295369377,420PubMedCrossRefGoogle Scholar
  4. 4.
    EUROASPIRE1997a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal resultsEur Heart J1815691582Google Scholar
  5. 5.
    Greenland, P, Knoll, MD, Stamler, J,  et al. 2003Major risk factors as antecedents of fatal and nonfatal coronary heart disease eventsJAMA290891897CrossRefPubMedGoogle Scholar
  6. 6.
    Alexander, RW 1994Inflammation and coronary artery diseaseN Engl J Med331468469CrossRefPubMedGoogle Scholar
  7. 7.
    Stary, HC, Chandler, AB, Glagov, S,  et al. 1994A definition of intimal fatty streak, and intermediate lesions of atherosclerosisCirculation8924622478PubMedGoogle Scholar
  8. 8.
    Stary, HC, Chandler, AB, Disnsmore, RE,  et al. 1995A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosisCirculation9213551374PubMedGoogle Scholar
  9. 9.
    Sidawy, AN 2000

    Basic considerations of the arterial wall in health and disease

    In: Rutherford Vascular Surgery5W. B. SaundersPhiladelphia6072
    Google Scholar
  10. 10.
    Ross, R 1995Cell biology of atherosclerosisAnnu Rev Physio57791804CrossRefGoogle Scholar
  11. 11.
    Napoli, C, D’Armiento, FP, Mancini, FP,  et al. 1997Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesionsJ Clin Invest10026802690PubMedCrossRefGoogle Scholar
  12. 12.
    Faggiotto, A, Ross, R, Harker, L 1984Studies of hypercholesterolemia in the nonhuman primate: changes that lead to fatty streak formationAtherosclerosis4323340Google Scholar
  13. 13.
    Stary, HC 1996

    The histological classification of atherosclerotic lesions in human coronary arteries

    Fuster, VRoss, RTopol, EJ eds. Atherosclerosis and Coronary Artery Disease, Vol. 1Lippincott-RavenPhiladelphia463474
    Google Scholar
  14. 14.
    Higashi, Y, Sasaki, S, Nakagawa, K, Matsuura, H, Oshima, T, Chayama, K 2002Endothelial function and oxidative stress in renovascular hypertensionN Engl J Med34619541962CrossRefPubMedGoogle Scholar
  15. 15.
    Landmesser, U, Hornig, B, Drexler, H 2004Endothelial function: a critical determinant in atherosclerosis?Circulation109II2733CrossRefPubMedGoogle Scholar
  16. 16.
    Gonzales, MA, Selwyn, AP 2003Endothelial function, inflammation, and prognosis in cardiovascular diseaseAm J Med11599S106SCrossRefGoogle Scholar
  17. 17.
    Keller, TT, Mairuhu, AT, Kruif, MD,  et al. 2003Infections and endothelial cellsCardiovasc Res604048CrossRefPubMedGoogle Scholar
  18. 18.
    Steele, SR, Martin, MJ, Mullenix, PS, Crawford, JV, Cuadrado, DS, Andersen, CA 2004Carotid artery stenosis following radiation therapy for head and neck cancer—should we be more aggressive in focused high-risk population screening?Am J Surg187594598PubMedCrossRefGoogle Scholar
  19. 19.
    Al Aly, Z, Edwards, JC 2004Vascular biology in uremia: insights into novel mechanisms of vascular injuryAdv Chronic Kidney Dis11310318PubMedCrossRefGoogle Scholar
  20. 20.
    Basta, G, Schmidt, AM, Caterina, R 2004Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetesCardiovasc Res63582592CrossRefPubMedGoogle Scholar
  21. 21.
    Asanuma, Y, Oeser, A, Shintani, AK,  et al. 2003Premature coronary-artery atherosclerosis in systemic lupus erythematososusN Engl J Med34924072415CrossRefPubMedGoogle Scholar
  22. 22.
    Libby, P, Egan, D, Skarlatos, S 1997Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future researchCirculation9640954103PubMedGoogle Scholar
  23. 23.
    Albert, MA, Ridker, PM 2004Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosisRev Cardiovasc Med5S2227PubMedGoogle Scholar
  24. 24.
    Jonasson, L, Holm, J, Skalli, O, Bondjers, G, Hansson, GK 1986Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaqueArteriosclerosis6131138PubMedGoogle Scholar
  25. 25.
    Ito, T, Ikeda, U 2003Inflammatory cytokines and cardiovascular diseaseCurr Drug Targets Inflamm Allergy2257265PubMedCrossRefGoogle Scholar
  26. 26.
    Strom, A, Franzen, A, Wangnerud, C,  et al. 2004Altered vascular remodeling in osteopontin-deficient atherosclerotic miceJ Vasc Res41314322CrossRefPubMedGoogle Scholar
  27. 27.
    Yamaoka-Tojo, M, Tojo, T, Masuda, T,  et al. 2003C-reactive protein-induced production of interleuking-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndromeHeart Vessels18183187CrossRefPubMedGoogle Scholar
  28. 28.
    Damas, JK, Waehre, T, Yndestad, A,  et al. 2003Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and plateletsCirculation10726702676CrossRefPubMedGoogle Scholar
  29. 29.
    Linton, MF, Fazio, S 2003Macrophages, inflammation, and atherosclerosisInt J Obes Relat Metab Disord21S3540CrossRefGoogle Scholar
  30. 30.
    Jeziorska, M, McCollum, C, Wooley, DE 1997Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteriesJ Pathol183248Google Scholar
  31. 31.
    Bhakdi, S, Torzewski, M, Klouche, M, Hemmes, M 1999Complement and atherogenesis: binding of CRP to degraded nonoxidized LDL enhances complement activationArterioscler Thromb Vasc Biol1923482354PubMedGoogle Scholar
  32. 32.
    Leskinen, MJ, Kovanen, PT, Lindstedt, KA 2003Regulation of smooth muscle cell growth, function and death by activated mast cells—a potential mechanism for the weakening and rupture of atherosclerotic plaquesBiochem Pharmaeol6614931498CrossRefGoogle Scholar
  33. 33.
    Sheikine, Y, Hansson, GK 2004Chemokines and atherosclerosisAnn Med3698118CrossRefPubMedGoogle Scholar
  34. 34.
    Caterina, , Zampoli, A 2004From asthma to atherosclerosis—5-lipoxygenase, leukotrienes, and inflammationN Engl J Med35047CrossRefPubMedGoogle Scholar
  35. 35.
    Cracowski, JL 2004Isoprostanes: an emerging role in vascular physiology and disease?Chem Phys Lipids1287583CrossRefPubMedGoogle Scholar
  36. 36.
    Bombeli, T, Schwartz, BR, Harlan, JM 1998Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-l), ab integrin, and GPIbaJ Exp Med187329339CrossRefPubMedGoogle Scholar
  37. 37.
    Hamsten, A, Wiman, B, Faire, U, Blomback, M 1985Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarctionN Engl J Med31315571563PubMedCrossRefGoogle Scholar
  38. 38.
    Mawatari, K, Kakui, S, Harada, N,  et al. 2004Endothelin-1(1-31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamstersAtherosclerosis175203212CrossRefPubMedGoogle Scholar
  39. 39.
    Flak, E 1996

    Pathogenesis of plaque disruption

    Fuster, VRoss, RTopol, EJ eds. Atherosclerosis and coronary artery disease, Vol. 2Lippincott-RavenPhiladelphia492510
    Google Scholar
  40. 40.
    Ridker, PM, Hennekens, CH, Rifai, N 2001Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral vascular diseaseJAMA28524812485CrossRefPubMedGoogle Scholar
  41. 41.
    Liuzzo, G, Biasucci, LM, Gallimore, JR,  et al. 1994The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable anginaN Engl J Med331417424CrossRefPubMedGoogle Scholar
  42. 42.
    Kohler, HP, Grant, PJ 2000Plasminogen-activator inhibitor type 1 and coronary artery diseaseN Engl J Med34217921801CrossRefPubMedGoogle Scholar
  43. 43.
    Hoylaerts, M, Rijken, DC, Lijnen, HR, Collén, D 1982Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrinJ Biol Chem25729122919PubMedGoogle Scholar
  44. 44.
    Schneiderman, J, Sawdey, MS, Keeton, MR,  et al. 1992Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteriesProc Natl Acad Sci USA8969987002PubMedCrossRefGoogle Scholar
  45. 45.
    Juhan-Vague, I, Pyke, SDM, Alessi, MC, Jespersen, J, Haverkate, F, Thompson, SG 1996Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectorisCirculation9420572063PubMedGoogle Scholar
  46. 46.
    Held, C, Hjemdahl, P, Rehnqvist, N,  et al. 1997Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metroprolol: results from the Angina Prognosis Study in StockholmCirculation9523802386PubMedGoogle Scholar
  47. 47.
    Juhan-Vague, I, Roul, C, Alessi, MC, Ardissone, JP, Heim, M, Vague, P 1989Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patient—relationship with plasma insulinThromb Haemost61370373PubMedGoogle Scholar
  48. 48.
    Labarrere, CA, Pitts, D, Nelson, DR, Faulk, WP 1995Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipientsN Engl J Med33311111116CrossRefPubMedGoogle Scholar
  49. 49.
    Mazer, SP, Rabbani, LE 2004Evidence for C-reactive protein’s (CRP) role in vascular disease: atherothrombosis, immuno-regulation and CRPJ Thromb Thrombolysis1795105CrossRefPubMedGoogle Scholar
  50. 50.
    Torzewski, J, Torzewski, M, Bowyer, DE,  et al. 1998C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteriesArterioscler Thromb Vasc Biol2813861392Google Scholar
  51. 51.
    Dannenberg, RD, Szalai, AJ, Swaminathan, RV,  et al. 2003Increased thrombogenesis after arterial injury in human C-reactive protein-transgenic miceCirculation5;108512515CrossRefGoogle Scholar
  52. 52.
    Torzewski, M, Rist, C, Mortensen, RF,  et al. 2000C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesisArterioscler Thromb Vasc Biol2020942099PubMedGoogle Scholar
  53. 53.
    Chang, MK, Binder, CJ, Torzewski, M, Witztum, JL 2002C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipidsProc Natl Acad Sci USA99125115125117Google Scholar
  54. 54.
    Fu, T, Borensztajn, J 2002Macrophage uptake of LDL bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesionsBiochem J266195201Google Scholar
  55. 55.
    Zimmerman, MA, Selzman, CH, Cothren, C,  et al. 2003Diagnostic implications of C-reactive proteinArch Surg138220224CrossRefPubMedGoogle Scholar
  56. 56.
    Wang, TJ, Nam, BH, Wilson, PW,  et al. 2002Association of C-reactive protein and carotid atherosclerosis in men and women: the Framingham Heart StudyAtherioscler Thromb Vasc Biol2214121413Google Scholar
  57. 57.
    Ridker, PM, Cushman, M, Stampfer, MJ, Tracy, RP, Hennekens, CR 1998Plasma concentration of C-reactive protein and risk of developing peripheral vascular diseaseCirculation97425428PubMedGoogle Scholar
  58. 58.
    Berk, BC, Weintraub, WS, Alexander, RW 1990Elevation of C-reactive protein in “active” coronary artery diseaseAm J Cardiol65168172CrossRefPubMedGoogle Scholar
  59. 59.
    Toss, H, Lindahl, B, Siegbahn, A,  et al. 1887Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery diseaseCirculation9642044210Google Scholar
  60. 60.
    Haverkate, F, Thompson, SG, Pyke, SD,  et al. 1997Production of C-reactive protein and risk of coronary events in stable and unstable anginaLancet349462466CrossRefPubMedGoogle Scholar
  61. 61.
    Pietila, K, Harmoninen, A, Hermens, W,  et al. 1993Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus and open infarct-related coronary artery after thrombolytic therapyEur Heart J14915919PubMedGoogle Scholar
  62. 62.
    Labarrere, CA, Lee, JB, Nelson, DR,  et al. 2002C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective studyLancet3014361437Google Scholar
  63. 63.
    Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of carotid stenosis. J Am Coll Surg 2004;194(3S)Google Scholar
  64. 64.
    Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. C-reactive protein and traditional vascular risk factors in the prediction of carotid stenosis. Presented at the 19th Annual Meeting of the Western Vascular Society, Victoria, BC, September 2004Google Scholar
  65. 65.
    Alvarez Garcia, B, Ruiz, C, Chacon, P, Sabin, JA, Matas, M 2003High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaqueJ Vasc Surg3810181024CrossRefPubMedGoogle Scholar
  66. 66.
    Milazzo, D, Biasucci, LM, Luciani, N,  et al. 1999Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic eventsAm J Cardial84459461CrossRefGoogle Scholar
  67. 67.
    Buffon, A, Liuzzo, G, Biasucci, LM,  et al. 1999Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplastyJ Am Call Cardial3415121521CrossRefGoogle Scholar
  68. 68.
    Chew, DP, Bhatt, DL, Robbins, MA,  et al. 2001Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary interventionCirculation104992997PubMedCrossRefGoogle Scholar
  69. 69.
    Ridker, PM, Brown, NJ, Vaughan, DE,  et al. 2004Established and emerging plasma biomarkers in the prediction of first atherothrombotic eventsCirculation109IV-6IV19CrossRefGoogle Scholar
  70. 70.
    Pearson, TA, Mensah, GA, Alexander, RW,  et al. 2003Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart AssociationCirculation107499511CrossRefPubMedGoogle Scholar
  71. 71.
    Spieker, LE, Ruschitzka, F, Luscher, TF, Noll, G 2004HDL and inflammation and atherosclerosisCurr Drug Targets Immune Endocr Metabol Disord45157PubMedCrossRefGoogle Scholar
  72. 72.
    Pennathur, S, Bergt, C, Shao, B,  et al. 2004Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen speciesJ Biol Chem2794297742983CrossRefPubMedGoogle Scholar
  73. 73.
    Dandona, P, Aljada, A, Dhindsa, S, Garg, R 2003Insulin as an anti-inflammatory and antiatherosclerotic hormoneClin CornerstoneSuppl 4S1320CrossRefPubMedGoogle Scholar
  74. 74.
    Spanbroek, R, Habenicht, AJ 2003The potential role of antileukotriene drugs in atherosclerosisDrug News Perspect16485409PubMedCrossRefGoogle Scholar
  75. 75.
    Vishnevetsky, D, Kiyanista, VA, Gandhi, PJ 2004CD40 ligand: a novel target in the fight against cardiovascular diseaseAnn Pharmacother3815001508CrossRefPubMedGoogle Scholar
  76. 76.
    Puddu, P, Puddu, GM, Muscari, A 2003Peroxisome proliferators-activated receptors: are they involved in atherosclerosis progression?Int J Cardiol90133140CrossRefPubMedGoogle Scholar
  77. 77.
    Goings K, Steele SR, Martin MJ, Mullenix PS, Andersen CA. The inflammatory component of carotid stenosis: a case report. Presented at the 31st Annual Meeting of the Society for Military Vascular Surgery, Washington, DC, November 2003Google Scholar
  78. 78.
    Niederberger, E, Manderscheid, C, Grosch, S,  et al. 2004Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cellsBiochem Pharmacol15341350CrossRefGoogle Scholar
  79. 79.
    Tripathi, YB, Reddy, MM, Pandey, RS,  et al. 2004Anti-inflammatory properties of BHUx, a polyherbal fomulation to prevent atherosclerosisInflammopharmacology12131152CrossRefPubMedGoogle Scholar
  80. 80.
    Schonbeck, D, Libby, P 2004Inflammation, immunity and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?Circulation109II1826CrossRefPubMedGoogle Scholar
  81. 81.
    Viedt, C, Shen, W, Fei, J,  et al. 2003HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9Basic Res Cardiol98353361PubMedGoogle Scholar
  82. 82.
    Shishehbor, MH, Aviles, RJ, Brennan, ML,  et al. 2003Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapyJAMA28916751680CrossRefPubMedGoogle Scholar
  83. 83.
    Martin-Ventura, JL, Ortego, M, Esbrit, P,  et al. 2003Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosisStroke3417831789CrossRefPubMedGoogle Scholar
  84. 84.
    Greenberg, AS 2003The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinedionesJ Diabetes Complications17218228CrossRefPubMedGoogle Scholar
  85. 85.
    Schieffer, B, Bunte, C, Witte, J,  et al. 2004Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery diseaseJ Am Coll Cardiol44362368CrossRefPubMedGoogle Scholar
  86. 86.
    Sharman, MJ, Volek, JS 2004Weight loss leads to reductions in inflammatory biomarkers after a very low-carbohydrate and low-fat diet in overweight menClin Sci (Land)107365369CrossRefGoogle Scholar
  87. 87.
    Troseid, M, Lappegard, KT, Damas, JK,  et al. 2004Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndromeEur Heart J25349355CrossRefPubMedGoogle Scholar
  88. 88.
    Carr, S, Farb, A, Pearce, WH, Virmani, R, Vao, JS 1996Atherosclerotic plaque rupture in symptomatic carotid artery stenosisJ Vasc Surg23755765PubMedCrossRefGoogle Scholar
  89. 89.
    Rundek, T, Elkind, MS, Pittman, J,  et al. 2002Carotid intima-media thickness is associated with allelic variants of stromelysin-1, IL-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort StudyStroke3314201423CrossRefPubMedGoogle Scholar
  90. 90.
    Shaalan, WE, Cheng, H, Gerwertz, B,  et al. 2004Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammationJ Vase Surg40262269CrossRefGoogle Scholar
  91. 91.
    Bicknell CD, Foale R, Mudra H, Cheshire NJ. Biological and duplex features of carotid plaques predict embolization during carotid endoluminal intervention. Presented at the International Congress XVII on Endovascular Interventions, Phoenix, AZ, February 8-12, 2004Google Scholar
  92. 92.
    Fujitani RM, Gelfand D, Gordon IL, et al. Correlation between CTA-acquired images of carotid artery plaque morphology with clinical neurologic symptomatology. Presented at the 20th Annual Meeting of the Western Vascular Society, Victoria, BC, September 2004Google Scholar
  93. 93.
    Lang W, Balzer KM, Muller KM, Fellner FA. Risk evaluation of carotid plaque morphology by ultrasonographic gray scale analysis and angioscopy: can we detect high-risk plaques for carotid angioplasty? Presented at the International Congress XVII on Endovascular Interventions, Phoenix, AZ, February 8-12, 2004Google Scholar
  94. 94.
    Shapiro, M, Hanon, S, Misra, D 2004Drug-eluting stentsHosp Phys121120Google Scholar
  95. 95.
    Serruys, PW, Unger, F, Hout, BA,  et al. 1999The ARTS study (Arterial Revascularization Therapies Study)Semin Interv Cardiol4209219PubMedGoogle Scholar
  96. 96.
    Marx, SO, Marks, AR 2001Bench to bedside: the development of rapamycin and its application to stent restenosis [editorial]Circulation104852855PubMedGoogle Scholar
  97. 97.
    Morice, MC, Serruys, PW, Sousa, JE,  et al. 2002A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularizationN Engl J Med34617731780CrossRefPubMedGoogle Scholar
  98. 98.
    Serruys, PW, Degertekin, M, Tanabe, K,  et al. 2002Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting Velocty balloon-expandable stents in the treatment of patients with de novo native coronary artery Lesions) trialCirculation106798803PubMedCrossRefGoogle Scholar

Copyright information

© Annals of Vascular Surgery Inc. 2005

Authors and Affiliations

  • Philip S. Mullenix
    • 1
  • Charles A. Andersen
    • 2
  • Benjamin W. Starnes
    • 2
  1. 1.General Surgery Service, Department of SurgeryMadigan Army Medical CenterTacomaUSA
  2. 2.Vascular and Endovascular Surgery Service, Department of SurgeryMadigan Army Medical CenterTacomaUSA

Personalised recommendations